Article detail · 2023
Trastuzumab deruxtecan versus treatment of physicians choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Journal
LANCETISSN 0140-6736
The ISSN points to another catalog journal; the name is from the YÖKSİS record.
YÖKSİS
OpenAlex
Open access · green
SJR Q1
JCR Q1
Citations 374
Top 1%
Percentile 99.9%
FWCI 42.0
- Year
- 2023
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue LANCET
- Catalog match (ISSN) The Lancet
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
374 citations
OpenAlex cited_by_count (cache / database)
5 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 2025
- Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study 2026
- Real-world outcomes of trastuzumab deruxtecan in patients with HER2+metastatic breast cancer: Turkish oncology group multicenter study 2026
- Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure 2026
- Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure 2026